SLC5A2 and diabetic kidney disease: Despite treatment with renin-angiotensin system (RAS) and SGLT2 inhibitors, a proportion of patients still progress to end-stage kidney disease (ESKD), suggesting the involvement of alternative pathological processes in the development of DKD [7].